Cantor Fitzgerald Comments on ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will post earnings per share of $0.05 for the year. Cantor Fitzgerald has a "Overweight" rating and a $8.00 price target on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.28) per share.

Several other research firms have also commented on ESPR. Needham & Company LLC reiterated a "buy" rating and set a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. HC Wainwright reiterated a "buy" rating on shares of Esperion Therapeutics in a report on Friday, January 10th. The Goldman Sachs Group began coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target on the stock. Finally, StockNews.com lowered Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $7.30.

Esperion Therapeutics Trading Up 0.7 %

ESPR traded up $0.02 on Wednesday, hitting $2.17. 4,111,691 shares of the company's stock were exchanged, compared to its average volume of 4,966,104. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The firm has a 50-day moving average price of $2.46 and a 200-day moving average price of $2.18. The stock has a market cap of $426.59 million, a price-to-earnings ratio of -3.38 and a beta of 1.03.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). The company had revenue of $51.63 million for the quarter, compared to analysts' expectations of $55.44 million. During the same quarter in the prior year, the company earned ($0.37) earnings per share.

Institutional Trading of Esperion Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ESPR. Wasatch Advisors LP increased its stake in Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock worth $38,521,000 after purchasing an additional 6,483,070 shares during the period. Marshall Wace LLP increased its stake in Esperion Therapeutics by 94.2% during the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company's stock worth $9,554,000 after purchasing an additional 2,087,635 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in Esperion Therapeutics during the third quarter worth about $606,000. Anson Funds Management LP purchased a new stake in Esperion Therapeutics during the third quarter worth about $540,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company's stock worth $1,174,000 after purchasing an additional 295,378 shares during the period. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.